deltatrials
Completed PHASE1/PHASE2 INTERVENTIONAL 2-arm NCT04431258

ABTL0812 in Combination With FOLFIRINOX for First-line Treatment of Metastatic Pancreatic Study (PanC-ASAP)

A Phase I Open Label Followed by a Phase II Randomized, Controlled Study to Assess the Efficacy and Safety of ABTL0812 in Combination With FOLFIRINOX for First-line Treatment of Metastatic Pancreatic

Sponsor: Ability Pharmaceuticals SL

Conditions Pancreatic Cancer
Interventions ABTL0812 Folfirinox Placebo
Updated 18 times since 2020 Last updated: Mar 15, 2024 Started: May 6, 2021 Primary completion: Jan 10, 2024 Completion: Jan 10, 2024
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1/PHASE2 trial investigates Pancreatic Cancer and is currently completed. Ability Pharmaceuticals SL leads this study, which shows 18 recorded versions since 2021 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Jul 2020 – ~Jan 2021 · 6 months · monthly snapshot~Jan 2021 – ~Mar 2021 · 59 days · monthly snapshot~Mar 2021 – ~Sep 2021 · 6 months · monthly snapshot~Sep 2021 – ~Mar 2022 · 6 months · monthly snapshot~Mar 2022 – ~Jul 2022 · 4 months · monthly snapshot~Jul 2022 – ~Sep 2022 · 2 months · monthly snapshot~Sep 2022 – ~Nov 2022 · 2 months · monthly snapshot~Nov 2022 – ~Dec 2022 · 30 days · monthly snapshot~Dec 2022 – ~Mar 2023 · 3 months · monthly snapshot~Mar 2023 – ~Apr 2023 · 31 days · monthly snapshot~Apr 2023 – ~May 2023 · 30 days · monthly snapshot~May 2023 – ~Aug 2023 · 3 months · monthly snapshot~Aug 2023 – ~Dec 2023 · 4 months · monthly snapshot~Dec 2023 – ~Apr 2024 · 4 months · monthly snapshot~Apr 2024 – ~Jul 2024 · 3 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

18 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE1/PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE1/PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  4. Apr 2024 — Jul 2024 [monthly]

    Completed PHASE1_PHASE2

    Status: Recruiting → Completed

  5. Dec 2023 — Apr 2024 [monthly]

    Recruiting PHASE1_PHASE2

▶ Show 13 earlier versions

  1. Aug 2023 — Dec 2023 [monthly]

    Recruiting PHASE1_PHASE2

  2. May 2023 — Aug 2023 [monthly]

    Recruiting PHASE1_PHASE2

  3. Apr 2023 — May 2023 [monthly]

    Recruiting PHASE1_PHASE2

  4. Mar 2023 — Apr 2023 [monthly]

    Recruiting PHASE1_PHASE2

  5. Dec 2022 — Mar 2023 [monthly]

    Recruiting PHASE1_PHASE2

  6. Nov 2022 — Dec 2022 [monthly]

    Recruiting PHASE1_PHASE2

  7. Sep 2022 — Nov 2022 [monthly]

    Recruiting PHASE1_PHASE2

  8. Jul 2022 — Sep 2022 [monthly]

    Recruiting PHASE1_PHASE2

  9. Mar 2022 — Jul 2022 [monthly]

    Recruiting PHASE1_PHASE2

  10. Sep 2021 — Mar 2022 [monthly]

    Recruiting PHASE1_PHASE2

    Status: Not Yet Recruiting → Recruiting

  11. Mar 2021 — Sep 2021 [monthly]

    Not Yet Recruiting PHASE1_PHASE2

  12. Jan 2021 — Mar 2021 [monthly]

    Not Yet Recruiting PHASE1_PHASE2

  13. Jul 2020 — Jan 2021 [monthly]

    Not Yet Recruiting PHASE1_PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Ability Pharmaceuticals SL
Data source: Ability Pharmaceuticals SL

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

A Coruña, Spain , Alicante, Spain , Badalona, Spain , Barcelona, Spain , Boston, United States , Cincinnati, United States , Dijon, France , Girona, Spain , Haifa, Israel , Jerusalem, Israel and 12 more locations